Ipsen Innovation — Sponsor Intelligence | 7 EU Trials

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

2 Completed trials

10 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (FiH)

Phase III: 3 Phase II: 2 Phase I (FiH): 2

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX 4 CLOSTRIDIUM BOTULINUM, NEUROTOXIN SEROTYPE A/B 4 CORABOTASE 2

All trials

7 total

A study to assess the effectiveness and safety of IPN10200 over time in adults with moderate to severe wrinkle-like lines between the eyebro… Pending

2025-522618-22-00 Phase III 2 countries CORABOTASE
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Recruiting

2024-511101-28-00 Phase II 5 countries CLOSTRIDIUM BOTULINUM, NEUROTOXIN SEROTYPE A/B
A study of IPN10200 for the treatment of cervical dystonia in adults Recruiting

2024-519248-34-00 Phase II 6 countries CLOSTRIDIUM BOTULINUM, NEUROTOXIN SEROTYPE A/B
A study to assess the safety and efficacy of IPN10200 in adult participants with moderate to severe upper facial lines Recruiting

2024-512782-14-00 Phase I (FiH) 2 countries BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX; CLOSTRIDIUM BOTULINUM, NEUROTOX…
A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting

2023-507202-14-00 Phase I (FiH) 10 countries BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX; CLOSTRIDIUM BOTULINUM, NEUROTOX…
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended

2023-504827-17-00 Phase III 5 countries BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended

2023-504839-40-00 Phase III 5 countries BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX

Showing 1–7 of 7 trials

← All sponsors A–Z